The Insulin Resistance and Atherosclerosis Study (IRAS) is a multicenter study of the relationship between insulin resistance and cardiovascular disease (CVD) and its risk factors in a tri-ethnic (African-American, Hispanic, and non-Hispanic white) population aged 40 to 69 years at baseline. The study population was selected to insure adequate numbers of participants within gender and glucose tolerance groups (normal, impaired glucose tolerance, and non-insulin dependent diabetes mellitus [NIDDM]). IRAS is the first large epidemiologic study to include detailed measurements of insulin sensitivity and secretion. During the first four years of funding the IRAS investigators successfully designed and implemented the first phase of the study -- a cross-sectional evaluation of 1,626 participants. The current proposal requests an additional five years of funding for the prospective follow-up and reexamination of the IRAS cohort. The requested funding period consists of three phases. During the first phase (Y05 and Y06), the investigators propose to conduct two substudies. The first will address the measurement of insulin sensitivity in individuals with NIDDM. This study will evaluate four alternative techniques for measuring insulin sensitivity in 50 non-IRAS volunteers. The second substudy will address methodologic issues in the measurement of obesity and body fat distribution in a tri-ethnic subgroup of 240 IRAS participants. In addition, all IRAS participants will be contacted annually for incident cardiovascular and other major health events. During the second phase, (Y07 and Y08), a follow-up examination of the IRAS cohort will be conducted with the goal of determining predictors of changes in insulin sensitivity, cardiovascular risk factors, measures of atherosclerosis development, and incident cardiovascular events. Additionally, throughout the first four years (Y05-Y08), major effort will be continued to be devoted to the analysis and reporting of the cross- sectional data from the first IRAS examination. The final phase (Y09) will include database closure and archival, and analysis and reporting of the longitudinal results.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01HL055208-01
Application #
2233753
Study Section
Special Emphasis Panel (ZHL1-CCT-H (S1))
Project Start
1995-09-30
Project End
2000-08-31
Budget Start
1995-09-30
Budget End
1996-08-31
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Festa, A; Haffner, S M; Wagenknecht, L E et al. (2013) Longitudinal decline of ?-cell function: comparison of a direct method vs a fasting surrogate measure: the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab 98:4152-9
Olson, Nels C; Callas, Peter W; Hanley, Anthony J G et al. (2012) Circulating levels of TNF-? are associated with impaired glucose tolerance, increased insulin resistance, and ethnicity: the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab 97:1032-40
Williams, Ken; Tchernof, Andre; Hunt, Kelly J et al. (2008) Diabetes, abdominal adiposity, and atherogenic dyslipoproteinemia in women compared with men. Diabetes 57:3289-96
Festa, Andreas; Williams, Ken; Hanley, Anthony J G et al. (2008) Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57:1638-44
Festa, Andreas; Williams, Ken; D'Agostino Jr, Ralph et al. (2006) The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 55:1114-20
Festa, Andreas; Williams, Ken; Tracy, Russell P et al. (2006) Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 113:1753-9
Festa, Andreas; Williams, Ken; Hanley, Anthony J G et al. (2005) Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 111:3465-72
Festa, Andreas; D'Agostino Jr, Ralph; Hanley, Anthony J G et al. (2004) Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 53:1549-55
Festa, Andreas; Hanley, Anthony J G; Tracy, Russell P et al. (2003) Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 108:1822-30
Festa, Andreas; D'Agostino Jr, Ralph; Rich, Steven S et al. (2003) Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation 107:2422-7

Showing the most recent 10 out of 14 publications